Denzel Valentine (Chicago Bulls) with a 2-pointer vs the Phoenix Suns, 02/26/2021
Denzel Valentine (Chicago Bulls) with a 2-pointer vs the Phoenix Suns, 02/26/2021
The GOP Texas senator spun a Politico article to bash the president, and Twitter unloaded on him.
Prime minister among political leaders hailing ‘extraordinary’ life of service
Leverkusen, Germany, April 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its consolidated results for the fiscal year ended December 31, 2020. At the same time, the Company provided an overview of current operational and clinical developments. Key financial figures FY2020 Revenue decreased by 3% to EUR 30.3 million compared to EUR 31.3 million in 2019;Loss from operations amounted to EUR 7.6 million compared to a loss of EUR 23.4 million in 2019;Net loss before tax was EUR 12.7 million compared to a loss of EUR 4.8 million in 2019;Cash and cash equivalents amounted to EUR 16.5 million as of December 31, 2020, compared to EUR 11.1 million as of December 31, 2019. Operational and clinical developments in 2020 and year-to-date Reorganization of the US business and restructuring of Biofrontera’s global sales organization;Exclusive license and supply agreement with Maruho Co., Ltd. for the development and commercialization of Ameluz® for all indications in East Asia and Oceania incl. an immediate one-time payment of EUR 6 million;Approval from the European Commission for the label extension of Ameluz® for the treatment of actinic keratosis (AK) on the entire body;Completion of the pharmacokinetics study and submission of the application for amendment of the product information to the U.S. Food and Drug Administration (FDA) to allow the simultaneous use of three tubes of Ameluz® per treatmentSubmission of the approval application to the FDA for a larger red-light source, the BF-RhodoLED® XL, for photodynamic therapy (PDT) in combination with Ameluz®. “Overall, we managed to steer Biofrontera well through a very challenging year - despite the decline in sales in our largest sales market, the USA. Early implemented cost-saving measures as well as cash inflows from the down payment received for the license agreement with Maruho Co., Ltd. and from the fully placed convertible bond in August successfully offset the negative impact caused by the decline in product sales. In this context, the strong fourth quarter also saw us reach operational breakeven at Group level for the first time," explained Prof. Dr. Lübbert, CEO of Biofrontera. "Encouragingly, sales in Germany continued to grow even in the pandemic year, driven by the EU approval extension for daylight PDT granted in 2018. We also recorded future-oriented strategic successes on the regulatory and clinical side. The EU approval extension for Ameluz® received in March, which now allows PDT treatment of mild and moderate actinic keratoses not only on the head but also on the entire body on label provided a further unique selling point for Ameluz®. The completion of the pharmacokinetics study, which tested the safety of PDT with the simultaneous application of up to three tubes of Ameluz®. represented another major milestone for us. The study report was submitted to the FDA in February 2021 with the aim of removing a restriction in the product information on the use of only one tube per treatment. This is a prerequisite for the treatment of larger body areas with several tubes of Ameluz® as well as for the alignment of reimbursement modalities compared to the competitor product in the USA and thus an increase in the competitiveness of Ameluz® in this important market. Furthermore, to complement this progress with an optimized light source, Biofrontera has developed a new lamp model, the BF-RhodoLED® XL, which can be used to illuminate larger skin areas." in EUR thousands2020 2019 Q4 2020Q4 2019Total revenue30,346 31,265 9,516 12,206 Research and development costs(4,789)(4,636)(1,386)(1,421)General and administrative costs(9,150)(16,275)(2,268)(4,167)Sales costs(20,482)(28,856)(4,142)(8,221)Profit (loss) from operations(7,611)(23,377)753 (2,284)Other (expenses) and income(2,418)21,184 (788)356 Net loss before tax(12,697)(4,777)(1,062)(2,253) Outlook and guidance 2021The Biofrontera Group provides the following guidance for the full year 2021, which reflects the Group's assessment regarding the timing and speed of recovery from the pandemic. We expect that due to the vaccination programs, the pandemic will slowly subside in our key sales markets, resulting in a growth momentum in the second half of 2021. However, our sales and thus business activities largely depend on the further infection trend and the associated easing of containment measures. Respecting these circumstances, the Group expects revenue from product sales of EUR 25 to 32 million in fiscal year 2021. EBITDA and EBIT will be introduced as key performance indicators in our reporting starting in 2021. Both have become established internationally as target metrics and will replace the previously reported key performance indicator result from operating activities.Based on the above assumptions, the Biofrontera Group expects EBITDA (loss) to be between EUR (11) million and EUR (14) million and EBIT (loss) between EUR (13) million and EUR (16) million in 2021. From today's perspective, the Biofrontera Group has sufficient liquidity available for the coming 12 months, taking into account the earnings expectations for 2021, cash on hand in the amount of EUR 16.5 million as of December 31, 2020 as well as the capital increase carried out in February 2021. Commercialization of Ameluz® in the USA Revenues generated from sales in the U.S.A. were EUR 16.6 million, compared to EUR 23.3 million in 2019, representing a decrease of 29% year-on-year. Revenues include EUR 0.3 million from product sales of Xepi® (previous year: EUR 0.6 million). As reported above, Biofrontera was directly affected by the global coronavirus crisis from mid-March 2020. From that point on, rising infection rates and the official recommendation of the American Academy of Dermatology to provide patients with remote diagnosis and treatment whenever possible led to significantly declining patient numbers and extensive, albeit temporary, practice closures. In the wake of this, our U.S. sales in particular declined sharply. As a result, the wholly owned US-subsidiary Biofrontera Inc. initiated extensive cost-saving measures, including headcount reductions. After sales of our products initially fell to almost zero in April 2020, we observed a slow recovery of our U.S. business again in the summer and later the first signs of stabilization in line with the usual seasonality. In many parts of the U.S., doctors' offices reopened during the second half of the year, at least in part, and patients showed increasing willingness to undergo treatment for actinic keratosis. The fourth quarter of 2020 again experienced a seasonally strong increase in sales, but overall sales in this quarter also remained below the level of the previous year, in part due to the so-called second wave of coronavirus infections. Commercialization of Ameluz® in EuropeRevenue from product sales in Germany increased by approximately 11% to EUR 5.1 million in fiscal 2020 compared to EUR 4.6 million in 2019, despite Corona-related restrictions. In the rest of Europe, the pandemic led to a decline in sales, with product sales of EUR 2.1 million compared to EUR 2.6 million in the prior-year period. In Germany our sales team successfully leveraged an approval extension granted in March 2020 to include the treatment of actinic keratoses on the body and extremities, as well as recent study results, to promote the benefits of Ameluz® to dermatologists even during the crisis. The advantages of daylight-PDT, which could be performed in good weather without immediate contact with doctors, became particularly evident during the summer months. Spain experienced a very positive sales development at the beginning of the year prior to the outbreak of the pandemic, after which business declined sharply due to the strict lockdown regulations there. In the United Kingdom, sales remained at a low level for almost the entire year due to the pandemic. Regional expansion of the commercialization of Ameluz® On March 13, 2020, the Company announced that it had signed a non-binding term sheet for an exclusive license and supply agreement with medac GmbH Sp. z o.o., Warsaw, the Polish subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH, for the commercialization of Ameluz® and BF-RhodoLED® in Poland. A final agreement is expected to be signed in 2021. On April 20, 2020, Biofrontera concluded an exclusive license and supply agreement with Maruho Co., Ltd. (Maruho) for the development and commercialization of Ameluz® for all indications in East Asia and Oceania. As part of the licensing agreement, Biofrontera received a one-time payment of EUR 6.0 million from Maruho. In addition, Biofrontera will receive future payments pending on the achievement of certain regulatory and sales milestones as well as royalties on sales. On December 7, 2020, the Company announced that its wholly owned subsidiary Biofrontera Pharma GmbH and Galenica AB, Malmö, Sweden (Galenica AB), signed an exclusive license and supply agreement for the commercialization of both Ameluz® and BF-RhodoLED® in in Schweden, Norwegen, Dänemark, Finnland und Island. According to the agreement, Galenica AB receives exclusive distribution rights for these regions and a right of first refusal for commercialization in the Baltic States. After the amicable termination of the agreement between Biofrontera and the former distribution partner for these regions, Galenica AB is now working towards the reintroduction of the products in Scandinavia by mid-2021. Regulatory and clinical progress Based on a positive assessment by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on February 3, 2020, the European Commission granted the formal label extension for Ameluz® on March 10, 2020, which now also covers the treatment of mild and moderate actinic keratoses (AK) on the extremities and trunk/neck with photodynamic therapy (PDT). In addition, the results of the follow-up phase of the clinical comparative study on daylight PDT with Ameluz® and Metvix® were included in the product information (SmPC). Ameluz® showed significantly lower recurrence rates after 12 months at 19.5% compared to competitor Metvix® at 31.2%. In October 2020, the clinical phase of the pharmacokinetics study (PK study) in the USA was concluded. The PK study tested the safety of PDT for the treatment of actinic keratoses on larger or multiple areas with the simultaneous use of up to three tubes of Ameluz®. The study report was submitted to the FDA in February 2021 with the objective of removing a restriction in the prescribing information for the use of only one tube per treatment. In addition, the development of the new BF-RhodoLED® XL lamp, which enables the use of Ameluz® across larger skin areas, was completed. The application for approval was submitted to the FDA in March 2021. Patient recruitment for the Phase III trial for the treatment of basal cell carcinoma (BCC) with Ameluz® in the USA continued in 2020 despite the pandemic. Conference callConference calls for shareholders and interested investors will be held on Tuesday, April 13, 2021, at the following times: In German, April 13, 2021, 10:00 am CEST (4:00 am EST)Dial-in number: +49 69201744220 Conference code: 35968911# In English, April 13, 2021, 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 21491700# Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.-End- Biofrontera AGPamela Keck, Head of Investor Relationsir@biofrontera.com+49-214-87632-0 About Biofrontera: Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi® for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin. Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ. www.biofrontera.com. Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.
Symone shared the skincare tips she learned on the set of "Rupaul's Drag Race." The post ‘Rupaul’s Drag Race’ finalist Symone dishes her post-drag skincare secrets appeared first on In The Know.
An Italian news website published photos it says were taken at lunchtime on Sunday of Ibrahimovic with friends, all without masks and surrounded by wine glasses, in the restaurant which should have been closed to on-site diners.
(Bloomberg) -- Ecuadorean bonds rallied after career banker Guillermo Lasso won the presidential election with a late surge in support, calming investors who thought his opponent was likely to lead the default-prone country into insolvency once again.Lasso beat out economist Andres Arauz, a left-wing protege of former President Rafael Correa, by a solid margin in Sunday’s runoff vote. Arauz, who conceded defeat, won February’s first round by 13 percentage points.It was a massive relief for bondholders, who bid up the country’s benchmark notes to their biggest gain since they were restructured just eight months ago. Ecuadorean debt had been trading at levels that signaled broad investor skepticism amid worry that a victory for Arauz would lead to unsustainable levels of social spending and an inevitable default from a politician who promised to prioritize the poor over the powerful.Lasso, a 65-year-old self-made millionaire and father of five, was largely seen as representing the establishment, having vowed to uphold a $6.5 billion financing agreement with the International Monetary Fund and to keep up payments on the country’s overseas bonds. In his victory speech Sunday evening, Lasso said he will work to create “the prosperity we all long for.”He received international congratulations from Latin American presidents and IMF Managing Director Kristalina Georgieva, who said “the IMF is committed to help Ecuador weather the pandemic, strengthen the economy and build a better future for all its people” via Twitter.“Lasso’s victory should reduce political uncertainty and raise the prospects of a fairly orthodox and market-friendly macro policy agenda,” Goldman Sachs Group Inc. analyst Tiago Severo wrote in a note.Morgan Stanley, Stifel Nicolaus & Co. and TPCG Valores were also among the firms to turn bullish on Ecuador’s bonds in the wake of Lasso’s victory, betting that gains would be extended beyond today’s rally.The country’s $3.7 billion of bonds due in 2030 surged almost 15 cents to 74 cents on the dollar, by far the biggest price jump since they were restructured.Ecuador’s southern neighbor Peru also held presidential elections Sunday, with exit polls suggesting a messy runoff after no candidate got near the threshold needed for a first-round win. Its overseas bonds edged lower.With some 99% of votes counted in Ecuador, Lasso had 52.5% to 47.5 in% for Arauz.Why Ecuador’s Runoff Vote Matters for the Bond Market: QuickTakeThe campaign for control of Ecuador, an oil exporter and world-leading producer of bananas, shrimp and the balsa wood crucial for wind-turbine rotors, has implications beyond is borders.Arauz, 36, who pledged to use central bank reserves to pay poor families, had been expected to strengthen ties with left-leaning governments in the region including in Cuba, Mexico, Venezuela and Argentina. Lasso’s win represents more of a focus on ties with Washington, and with U.S.-aligned governments in countries such as Chile, Colombia and Brazil.Sigh of ReliefWhile bond investors breathed a sigh of relief, Lasso won’t have an easy time running the country of 17 million people amid a sluggish vaccination campaign. Last year the dollarized economy contracted 7.8% as the pandemic decimated activity, its worst performance since at least the 1970s.To govern successfully, Lasso will have to establish a working relationship with the National Assembly, where his backers hold just 31 of the 137 seats. He will also need to reach out to the more than 1.8 million Ecuadorians who voided their votes, including many from indigenous movements.Lasso will find it tough to implement unpopular economic policies since legislators from other parties will be reluctant to spend their political capital on his behalf, according to Maria Jose Calderon, political scientist at the Pontifical Catholic University in Quito.Creating JobsThe president-elect has said he’ll promote policies that boost investment and private-sector job creation, and will phase out a tax on taking money out of the country. He’s also promised to boost the monthly minimum wage to $500 from $400, and oversee the vaccination of 9 million people against Covid-19 during his first 100 days in office.Even if Lasso encounters challenges in implementing his political agenda, it will be easier for him and the IMF to find a middle ground as they negotiate timelines for austerity measures, according to Nathalie Marshik, head of emerging-market sovereign research at Stifel Nicolaus & Co. in New York.During the campaign, Lasso rejected increasing taxes to meet IMF austerity targets, even though Ecuador has one of the region’s lowest value-added taxes at 12%. Recent gains in crude oil, the country’s biggest export, as well as the close to $1 billion the country can expect to gain from the IMF’s planned increase in special drawing rights will give him previously unexpected fiscal breathing room.“This could offer the new government some room to postpone some of the planned measures or design an easier-to-swallow version of tax reform,” Barclays analyst Alejandro Arreaza said in a research note. Ecuador might even be tempted to return to the financial market sooner than planned under the IMF deal if yields fall low enough, Arreaza added.(Updates with congratulations including the IMF in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Phoebe Bridgers smashed her electric guitar into an amplifier at the end of her "SNL" debut. It sold for $101,500 to help support GLAAD.
Green jacket winners: They sit around in airports just like us!
Facebook plans to start rolling out notifications to connect people to state-specific information from their local health departments about how they can get vaccinated.
Officials ruled out a terrorist attack, with witness statements appearing to point to a targeted killing
South Carolina’s secondary is incredibly thin at the moment but the players like the chemistry they’ve built up.
OverActive Media Corp. ("OverActive" or the "Corporation") and Abigail Capital Corporation (TSXV: ACC.P) ("ACC") are pleased to announce that all tranches of the previously announced private placements have closed, pursuant to which it raised aggregate gross proceeds of approximately $40 million from the sale of subscription receipts (the "Receipts") and common shares (the "Shares") at a price of $2.25 per Receipt or Share (the "Offerings"). The Corporation closed on approximately $1.9 million of additional proceeds on Friday, April 9, 2021 as part of the second closing.
SCOTTSDALE, AZ,, April 12, 2021 (GLOBE NEWSWIRE) -- AMMO, Inc. (Nasdaq: POWW) (“AMMO” or the “Company”), a premier American ammunition and munition components manufacturer and technology leader, is pleased to announce that it will present at the Emerging Growth Conference on April 14, 2021 at 11:15 AM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company. To participate, please register at this unique registration link. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com. About the Emerging Growth Conference The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner. The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone. About AMMO, Inc. With its corporate offices headquartered in Scottsdale, Arizona. AMMO designs and manufactures products for a variety of aptitudes, including law enforcement, military, sport shooting and self-defense. The Company was founded in 2016 with a vision to change, innovate and invigorate the complacent munitions industry. AMMO promotes branded munitions as well as its patented STREAK™ Visual Ammunition, /stelTH/™ subsonic munitions, and armor piercing rounds for military use. For more information, please visit: www.ammo-inc.com. Forward Looking Statements This press release contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of the statements. Accordingly, investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. Such forward-looking statements are based on our current beliefs and expectations, which we believe are reasonable. However, forward-looking statements are subject to significant known and unknown risks and uncertainties that may cause actual results, performance or achievements in future periods to differ materially from those assumed, projected or contemplated in the forward-looking statements. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we include in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports filed on Form 8-K. Investor Contact:Rob Wiley, CFOAMMO, Inc.Phone: (480) 947-0001IR@ammo-inc.com
National Rail has said that it will address its “internal accessibility process” after it failed to pick up issues with its tribute to Prince Philip. National Rail, however, had not implemented a way to revert the change - something that affected its own employees. One user, asking National Rail about the issue on Twitter because they “struggle” with grey colours, was told on 11 April by the company: “Unfortunately, I do not believe there is [a way to revert the change].”
“Promising Young Woman,” the dark comedy starring Carey Mulligan, will be offered for free to college students. Focus Features, the film’s backer, has partnered with RAINN, the country’s largest anti-sexual violence organization, to host virtual screenings of the film on April 15. Following the showing, Laverne Cox will moderate a conversation with her co-star Mulligan […]
Air France-KLM has launched a share issue to raise about 988 million euros ($1.2 billion) to strengthen its liquidity and finance its general needs in the context of the COVID-19 crisis, it said on Monday. The French state, which holds 14.3% of the airline's share capital, has committed to subscribe up to a maximum of 65.9% of the capital increase, so as not to hold more than 29.9% of the company's share capital following completion of the operation. The Dutch state, which holds 14.0% of the share capital, has informed the company of its intention not to participate in the capital increase.
Terren Frank joined the Frogs as a four-star prospect from the LA area.
The picture of the then two-year-old with the Duke of Edinburgh was taken in Norfolk by the Duchess of Cambridge.
Japan's Wakayama Workcation Locations Wakayama, Japan--(Newsfile Corp. - April 12, 2021) - Japan's Wakayama Prefecture is proud to announce new workcation destinations.Deep breaths. One foot in front of the other. I'm ascending a section of the Kumano Kodo, a network of ancient roads that run through the mountains of Japan's Kii Peninsula. A canopy of cedars towers above me. The stones that comprise my path have been worn smooth after centuries under the feet ...
Failure is not something one would associate with music mogul, entrepreneur, & philanthropist Percy “Master P” Miller. The iconic rapper and businessman has been a model of success for decades, but one message Miller wants to give to folks who are following their dreams. Success does not come overnight, and failure is not the end.